一年的随访研究发现紫杉醇涂层球囊对于预防支架内再狭窄具有更佳的效果。 1-year follow-up study finds paclitaxel-coated balloons superior for in-stent restenosis prevention.

AGENT IDE 研究涉及 600 名支架内再狭窄患者，发现在一年的随访中，紫杉醇涂层球囊在预防目标病变失败方面优于未涂层球囊。 The AGENT IDE study, involving 600 patients with in-stent restenosis, found that paclitaxel-coated balloons were superior to uncoated balloons in preventing target lesion failure at one-year follow-up. 该药物涂层球囊为治疗冠状动脉支架内再狭窄提供了一种有效的治疗策略，并且是美国批准的第一个冠状动脉药物涂层球囊。 The drug-coated balloon offers an effective treatment strategy for managing coronary in-stent restenosis and is the first coronary drug-coated balloon to be approved in the United States.